Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP

Blood

Volumn 111, Issue 9, 2008, Pages 4664-4667

  Taskinen, Minna ^a   Karjalainen Lindsberg, Marja Liisa ^b   Leppä, Sirpa ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER INFILTRATION; CANCER RELAPSE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; FOLLICULAR LYMPHOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MAST CELL; PRIORITY JOURNAL; PROGNOSIS; CELL COUNT; CLINICAL TRIAL; MIDDLE AGED; MORTALITY; NEOPLASM; PATHOLOGY; RECURRENT DISEASE; SURVIVAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL COUNT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MAST CELLS; MIDDLE AGED; NEOPLASMS; PREDNISONE; PROGNOSIS; RECURRENCE; SURVIVAL ANALYSIS; VINCRISTINE;

EID: 47149105261     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2007-11-125823     Document Type: Article

References (24)

1. de Jong D. Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologicfactors. J Clin Oncol. 2005;23:6358-6363.
2. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2005;106:3725-3732.
3. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood. 2005;105:1417-1423.
4. Forstpointner R, Dreyling M. Repp R, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FGM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood. 2004;104:3064-3071.
5. Forstpointner R, Unterhalt M, Dreyling M, et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab. fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood. 2006;108:4003-4008.
6. Herald M, Haas A, Sraok S, et al. Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. J Clin Oncol. 2007;25:1986-1992.
7. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergrouptrial. Blood. 2006;108:3295-3301.
8. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood. 2004;104:1258-1265.
9. Buske C, Hoster E, Dreyling M, Hasford J, Unterhalt M, Hiddemann W. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediateor low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood. 2006;108:1504-1508.
10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med. 2004;351:2159-2169.
11. HarjunpääA. Taskinen M, Nykter M. et al. Differential gene expression in non-malignant tumour microenvironment is associated with outcome in follicular lymphoma patients treated with rituximab and CHOP. Br J Haematol. 2006;135:33-42.
12. Alvaro T, Lejeune M, Camacho Fl, et al. The presence of STATI-positive tumor-associated macrophages and their relation to outcome in patients with follicular lymphoma. Haematologica. 2006;91:1605-1612.
13. Alvaro T, Lejeune M, Salvado MT, et al. Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients. J Clin Oncol. 2006;24:5350-5357.
14. Carreras J, Lopez-Guillermo A, Fox BC, et al. High numbers of tumor-infiltrating FOXP3positive regulatory T cells are associated with improved overall survival in follicular lymphoma. Blood. 2006;108:2957-2964.
15. Farinha P, Masoudi H. Skinnider BF, et al. Analysis of multiple biomarkers shows that lymphomaassociated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL). Blood. 2005:106:2169-2174.
16. + cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol. 2006;24:5052-5059.
17. Taskinen M, Karjalainen-Lindsberg ML, Nyman H, Eerola LM, Leppa S. A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-Doxorubicin- vincristineprednisone. Clin Cancer Res. 2007;13:5784-5789.
18. Canioni D, Salles G, Mounier N, et al. High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL2000 trial. J Clin Oncol. 2008;26:440-446.
19. Leder LD. [On the selective enzymecytochemical demonstration of neutrophilic myeloid cells and tissue mast cells in paraffin sections.]. Klin Wochenschr. 1964;42:553.
20. Hedstrom G, Berglund M, Molin D, et al. Mast cell infiltration is a favourable prognostic factor in diffuse large B-cell lymphoma. Br J Haematol. 2007;138:68-71.
21. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin's lymphoma. Br J Haematol. 2002;119:122-124.
22. Theoharides TC, Conti P. Mast cells: the Jekyll and Hyde of tumor growth. Trends Immunol. 2004;25:235-241.
23. Siberil S. Dutertre CA, Fridman WKTeillaud JL. Fcgamma R: The key to optimize therapeutic antibodies? Crit Rev Oncol Hematol. 2007:62:26-33.
24. Clynes RA, Towers TL. Presta LG. Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med. 2000:6;443-446.